AstraZeneca announces results of Phase 3 clinical trial sedaton and aspirin combination
-
Last Update: 2020-06-08
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
recently (September 3) AstraZeneca(http://published detailed results of phase 3 clinicaltrial(http://THEMISresults showed that a combination of ticagrelor and aspirin combined with aspirin reduced the relative risk of cardiovascular death, heart attack and stroke by 10 percent compared to single aspirinthat tegreo
Tegreo was approved by theFDA(http://as early as 2011 to reduce thrombosis in patients with acute coronary artery syndrometegrelo itself is an oral adenosine diphosphate (ADP) receptor reversible binding antagonistIt can choose to inhibit ADP's key receptor P2Y12, inhibit slateformation in the blood, and thus reduce recurrent thrombosishypothesis that THEMISTHEMIS is a multi-national, randomized double-blind phase 3 clinical trial designed to test the combination of tegres and aspirin to reduce the risk of major adverse cardiovascular events (MACE) The THEMIS trial, launched in early 2014, has recruited about 19,000 people with coronary artery disease and type 2 diabetes without prior myocardial infarction or stroke, the largest randomized trial to date in people with type 2 diabetes
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
